Home
Drugs
Azacitidine
Clinical Trials

Clinical Trials Related to Azacitidine

Related studies linked through entity extraction aliases.

Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia

Status: COMPLETED
Phase: PHASE2

Low-Dose Azacitidine, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma

Status: COMPLETED
Phase: PHASE1/PHASE2

Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma

Status: COMPLETED
Phase: PHASE1

Epigenetic Modulation in Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma

Status: TERMINATED
Phase: PHASE2

Azacitidine and Entinostat in Treating Patients With Metastatic Colorectal Cancer

Status: COMPLETED
Phase: PHASE2

Midostaurin and Azacitidine in Treating Elderly Patients With Acute Myelogenous Leukemia

Status: COMPLETED
Phase: PHASE1/PHASE2

Azacitidine in Treating Patients With Relapsed Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant

Status: COMPLETED
Phase: PHASE2

Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML)

Status: COMPLETED
Phase: PHASE3

Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) in Combination With Azacitidine for the Treatment of Myelodysplastic Syndrome (MDS)

Status: COMPLETED
Phase: PHASE1

Lenalidomide + Azacitidine for Adaptive Immunotherapy -> Auto SCT in Multiple Myeloma

Status: COMPLETED
Phase: NA

Evaluation of Azacitidine in Transfusion Dependent Patients With Low-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)

Status: COMPLETED
Phase: PHASE2

Azacitidine and Oxaliplatin In Treating Patients With Advanced Cancers Relapsed or Refractory to Any Platinum Therapy

Status: COMPLETED
Phase: PHASE1

Azacitidine and Lenalidomide for Acute Myeloid Leukemia

Status: COMPLETED
Phase: PHASE1/PHASE2

Azacitidine Combined to Epoetin Beta in International Prognostic Scoring System (IPSS) Low-risk and Intermediate-1 Myelodysplastic Syndrome (MDS) Patients, Resistant to Erythropoetin-stimulating Agents (ESA)

Status: COMPLETED
Phase: PHASE2

To Demonstrate Superiority of Decitabine Over Azacitidine in Subjects With Intermediate- or High-risk MDS.

Status: TERMINATED
Phase: PHASE4

Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Status: COMPLETED
Phase: PHASE2

A Study to Evaluate the Effectiveness of 5-Azacitidine and Bevacizumab in Advanced Renal Cell Carcinoma

Status: TERMINATED
Phase: PHASE1/PHASE2

Combination of 5-azacitidine and Lenalidomide in Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) Myelodysplastic Syndromes

Status: TERMINATED
Phase: PHASE1

Efficacy of 5-azacytidine Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

Status: COMPLETED
Phase: PHASE2

MLN4924 for the Treatment of Acute Myelogenous Leukemia, Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia

Status: COMPLETED
Phase: PHASE1